Syros Pharmaceuticals (SYRS) Competitors $0.0004 +0.00 (+100.00%) As of 05/22/2026 03:46 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock SYRS vs. SCPS, ARDS, TRVN, NAVB, and GNCAShould you buy Syros Pharmaceuticals stock or one of its competitors? MarketBeat compares Syros Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Syros Pharmaceuticals include Scopus BioPharma (SCPS), Aridis Pharmaceuticals (ARDS), Trevena (TRVN), Navidea Biopharmaceuticals (NAVB), and Genocea Biosciences (GNCA). These companies are all part of the "pharmaceutical products" industry. SYRS vs. SCPSSYRS vs. ARDSSYRS vs. TRVNSYRS vs. NAVBSYRS vs. GNCAHow does Syros Pharmaceuticals compare to Scopus BioPharma?Syros Pharmaceuticals (NASDAQ:SYRS) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk. Does the media refer more to SYRS or SCPS? In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score. Company Overall Sentiment Syros Pharmaceuticals Neutral Scopus BioPharma Neutral Which has more volatility and risk, SYRS or SCPS? Syros Pharmaceuticals has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.17, indicating that its share price is 117% less volatile than the broader market. Do institutionals & insiders believe in SYRS or SCPS? 91.5% of Syros Pharmaceuticals shares are held by institutional investors. 12.3% of Syros Pharmaceuticals shares are held by insiders. Comparatively, 5.1% of Scopus BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is SYRS or SCPS more profitable? Scopus BioPharma's return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Syros PharmaceuticalsN/A -3,369.56% -97.04% Scopus BioPharma N/A N/A N/A Which has higher valuation and earnings, SYRS or SCPS? Scopus BioPharma has lower revenue, but higher earnings than Syros Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSyros Pharmaceuticals$386K0.03-$164.57M-$3.03N/AScopus BioPharmaN/AN/A-$11.61MN/AN/A SummarySyros Pharmaceuticals beats Scopus BioPharma on 4 of the 7 factors compared between the two stocks.How does Syros Pharmaceuticals compare to Aridis Pharmaceuticals?Aridis Pharmaceuticals (NASDAQ:ARDS) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings. Do institutionals and insiders believe in ARDS or SYRS? 9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 5.5% of Aridis Pharmaceuticals shares are owned by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media prefer ARDS or SYRS? In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score. Company Overall Sentiment Aridis Pharmaceuticals Neutral Syros Pharmaceuticals Neutral Which has stronger valuation and earnings, ARDS or SYRS? Aridis Pharmaceuticals has higher earnings, but lower revenue than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAridis PharmaceuticalsN/AN/A-$30.37M$0.090.02Syros Pharmaceuticals$386K0.03-$164.57M-$3.03N/A Which has more volatility and risk, ARDS or SYRS? Aridis Pharmaceuticals has a beta of 49.37, meaning that its stock price is 4,837% more volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market. Is ARDS or SYRS more profitable? Aridis Pharmaceuticals' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Aridis PharmaceuticalsN/A N/A N/A Syros Pharmaceuticals N/A -3,369.56%-97.04% SummaryAridis Pharmaceuticals beats Syros Pharmaceuticals on 6 of the 9 factors compared between the two stocks.How does Syros Pharmaceuticals compare to Trevena?Syros Pharmaceuticals (NASDAQ:SYRS) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations. Is SYRS or TRVN more profitable? Trevena's return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Syros PharmaceuticalsN/A -3,369.56% -97.04% Trevena N/A N/A -119.55% Which has higher earnings and valuation, SYRS or TRVN? Trevena has higher revenue and earnings than Syros Pharmaceuticals. Trevena is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSyros Pharmaceuticals$386K0.03-$164.57M-$3.03N/ATrevena$443K0.02-$40.29M-$47.04N/A Do institutionals and insiders have more ownership in SYRS or TRVN? 91.5% of Syros Pharmaceuticals shares are held by institutional investors. Comparatively, 13.6% of Trevena shares are held by institutional investors. 12.3% of Syros Pharmaceuticals shares are held by insiders. Comparatively, 2.7% of Trevena shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media refer more to SYRS or TRVN? In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score. Company Overall Sentiment Syros Pharmaceuticals Neutral Trevena Neutral Which has more risk & volatility, SYRS or TRVN? Syros Pharmaceuticals has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market. Comparatively, Trevena has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market. SummarySyros Pharmaceuticals beats Trevena on 7 of the 10 factors compared between the two stocks.How does Syros Pharmaceuticals compare to Navidea Biopharmaceuticals?Syros Pharmaceuticals (NASDAQ:SYRS) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations. Is SYRS or NAVB more profitable? Navidea Biopharmaceuticals' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Syros PharmaceuticalsN/A -3,369.56% -97.04% Navidea Biopharmaceuticals N/A N/A N/A Do insiders & institutionals believe in SYRS or NAVB? 91.5% of Syros Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 12.3% of Syros Pharmaceuticals shares are owned by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more volatility and risk, SYRS or NAVB? Syros Pharmaceuticals has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market. Which has better earnings and valuation, SYRS or NAVB? Navidea Biopharmaceuticals has lower revenue, but higher earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSyros Pharmaceuticals$386K0.03-$164.57M-$3.03N/ANavidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A Does the media favor SYRS or NAVB? In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score. Company Overall Sentiment Syros Pharmaceuticals Neutral Navidea Biopharmaceuticals Neutral SummaryNavidea Biopharmaceuticals beats Syros Pharmaceuticals on 6 of the 9 factors compared between the two stocks.How does Syros Pharmaceuticals compare to Genocea Biosciences?Genocea Biosciences (NASDAQ:GNCA) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations. Is GNCA or SYRS more profitable? Genocea Biosciences' return on equity of -182.88% beat Syros Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Genocea BiosciencesN/A -182.88% -62.76% Syros Pharmaceuticals N/A -3,369.56%-97.04% Which has better valuation and earnings, GNCA or SYRS? Genocea Biosciences has higher revenue and earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenocea Biosciences$1.91M0.00-$33.20M-$0.61N/ASyros Pharmaceuticals$386K0.03-$164.57M-$3.03N/A Do insiders and institutionals believe in GNCA or SYRS? 0.6% of Genocea Biosciences shares are held by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media favor GNCA or SYRS? In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score. Company Overall Sentiment Genocea Biosciences Neutral Syros Pharmaceuticals Neutral Which has more risk & volatility, GNCA or SYRS? Genocea Biosciences has a beta of 1.61, meaning that its share price is 61% more volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market. SummaryGenocea Biosciences beats Syros Pharmaceuticals on 6 of the 9 factors compared between the two stocks. Get Syros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SYRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SYRS vs. The Competition ExportMetricSyros PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.65M$793.11M$6.44B$12.33BDividend YieldN/A4.84%2.76%5.28%P/E Ratio0.001.4621.2825.67Price / Sales0.03119.53553.3882.98Price / CashN/A20.0743.6856.73Price / Book0.007.5910.367.14Net Income-$164.57M-$3.91M$3.56B$335.80M7 Day PerformanceN/A0.57%5.11%3.02%1 Month PerformanceN/A77.79%3.53%2.48%1 Year PerformanceN/A126.61%34.13%35.08% Syros Pharmaceuticals Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SYRSSyros PharmaceuticalsN/A$0.00+100.0%N/A-98.7%$1.65M$386KN/A120Upcoming EarningsSCPSScopus BioPharmaN/A$0.00-33.3%N/AN/A$17KN/AN/A9Gap DownARDSAridis PharmaceuticalsN/A$0.00-92.9%N/A+750.0%$11KN/A0.0030Gap DownTRVNTrevenaN/A$0.01flatN/A-99.0%$11K$443KN/A40NAVBNavidea BiopharmaceuticalsN/AN/AN/AN/A$10K$8.13KN/A10 Related Companies and Tools Related Companies SCPS Alternatives ARDS Alternatives TRVN Alternatives NAVB Alternatives GNCA Alternatives SMFL Alternatives GNCAQ Alternatives CARM Alternatives CMRA Alternatives CALA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SYRS) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredYour computer is about to become a museum pieceFuturist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredYou have until June 1Macroeconomic strategist Dr. Mark Skousen believes June 1 marks a critical turning point for one of the most o...The Oxford Club | SponsoredI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...Brownstone Research | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
